Benjamin  Landry net worth and biography

Benjamin Landry Biography and Net Worth

General Counsel of Health Catalyst

Ben Landry is the General Counsel and Secretary of the Board, with responsibility for all aspects of legal and regulatory affairs at Health Catalyst, originally joining in July 2019 as Assistant General Counsel. Landry has ~15 years of private practice and in-house legal experience, primarily focused on healthcare and information technology. Prior to joining Health Catalyst, Landry worked at athenahealth, Inc. (NASDAQ: ATHN), a publicly traded healthcare IT company, for over 4 years in a variety of legal roles, including as Associate General Counsel, leading the corporate team that oversaw corporate governance, securities, mergers & acquisitions, strategic investments, international and other corporate functions. Landry helped support athenahealth's exploration of strategic alternatives in 2018 that ultimately led to closing a private equity-backed take-private transaction in February 2019, and helped lead aspects of post-transaction integration, including athenahealth's combination with another portfolio company owned by the acquirer.

Prior to joining athenahealth, Landry worked at a law firm in Boston for over 4 years, primarily focused on corporate, mergers & acquisitions and private equity, and worked at Raytheon Technologies Corporation (NYSE: RTX), a multinational aerospace and defense conglomerate, in the tax department. Landry received his bachelor's degree from Boston College and his law degree from the Northeastern University School of Law.

What is Benjamin Landry's net worth?

The estimated net worth of Benjamin Landry is at least $381.47 thousand as of September 5th, 2025. Mr. Landry owns 141,812 shares of Health Catalyst stock worth more than $381,474 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Landry may own. Learn More about Benjamin Landry's net worth.

How do I contact Benjamin Landry?

The corporate mailing address for Mr. Landry and other Health Catalyst executives is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. Health Catalyst can also be reached via phone at (801) 708-6800 and via email at [email protected]. Learn More on Benjamin Landry's contact information.

Has Benjamin Landry been buying or selling shares of Health Catalyst?

Benjamin Landry has not been actively trading shares of Health Catalyst during the last ninety days. Most recently, Benjamin Landry sold 6,175 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $3.35, for a transaction totalling $20,686.25. Following the completion of the sale, the general counsel now directly owns 141,812 shares of the company's stock, valued at $475,070.20. Learn More on Benjamin Landry's trading history.

Who are Health Catalyst's active insiders?

Health Catalyst's insider roster includes Jason Alger (CAO), Daniel Burton (CEO), Duncan Gallagher (Director), Bryan Hinton (CTO), Paul Horstmeier (COO), Bryan Hunt (CFO), Benjamin Landry (General Counsel), Daniel LeSueur (COO), Linda Llewelyn (Insider), James Nelli, Jr. (President), Daniel Orenstein (CEO), and Anita Pramoda (Director). Learn More on Health Catalyst's active insiders.

Are insiders buying or selling shares of Health Catalyst?

During the last year, insiders at the sold shares 16 times. They sold a total of 133,489 shares worth more than $823,828.03. The most recent insider tranaction occured on September, 5th when General Counsel Benjamin Landry sold 6,175 shares worth more than $20,686.25. Insiders at Health Catalyst own 2.6% of the company. Learn More about insider trades at Health Catalyst.

Information on this page was last updated on 9/5/2025.

Benjamin Landry Insider Trading History at Health Catalyst

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/5/2025Sell6,175$3.35$20,686.25141,812View SEC Filing Icon  
6/5/2025Sell6,057$3.94$23,864.58151,125View SEC Filing Icon  
3/6/2025Sell13,827$4.55$62,912.85160,437View SEC Filing Icon  
1/6/2025Sell2,500$7.52$18,800.0072,250View SEC Filing Icon  
12/6/2024Sell19,268$8.32$160,309.7672,250View SEC Filing Icon  
9/6/2024Sell2,466$7.39$18,223.74100,937View SEC Filing Icon  
9/6/2023Sell1,157$11.52$13,328.6428,187View SEC Filing Icon  
7/7/2023Sell1,179$11.14$13,134.0629,844View SEC Filing Icon  
6/6/2023Sell1,078$11.84$12,763.5229,844View SEC Filing Icon  
See Full Table

Benjamin Landry Buying and Selling Activity at Health Catalyst

This chart shows Benjamin Landry's buying and selling at Health Catalyst by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Health Catalyst Company Overview

Health Catalyst logo
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
Read More

Today's Range

Now: $2.69
Low: $2.66
High: $2.75

50 Day Range

MA: $2.84
Low: $2.03
High: $3.46

2 Week Range

Now: $2.69
Low: $2.02
High: $8.84

Volume

408,650 shs

Average Volume

850,892 shs

Market Capitalization

$190.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72